Author | Heather H. Cheng, MD, PhD


Targeting the Androgen Receptor Signaling Axis to Reduce Testosterone Levels in Prostate Cancer: How Low Should We Go?

August 15, 2014

ByHeather H. Cheng, MD, PhD|Celestia S. Higano, MD

It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.